Hangzhou Tigermed Consulting (300347) Stock Price, Fundamentals & Analysis

What 300347 does

Hangzhou Tigermed Consulting (300347) is a contract research organization that supports drug and medical device development. It operates in the Healthcare sector, specifically Diagnostics & Research, and is listed on the Shenzhen Stock Exchange. The company provides clinical trial operation services—including clinical pharmacology, regulatory affairs, pharmacovigilance, and medical translation—as well as laboratory and data management services across China and internationally.

Key numbers explained

• 56.81 CNY is the current share price, the latest trading value of one share.
• The trailing P/E ratio of 516.5 compares the price to the last 12 months of earnings per share (0.11 CNY), showing how the market prices each yuan of recent profit.
• The forward P/E ratio of 46.2 uses expected future earnings, offering a view of valuation based on analyst estimates rather than past results.
• 0.22% is the dividend yield, the annual dividend relative to the price; the company pays out 0% of earnings as dividends, with the next ex-dividend date on Jul 10, 2026.
• 0.35 is the beta, a measure of volatility relative to the market; a value below 1 suggests the stock tends to move less than the broader market.
• 11.8% is the operating margin, showing how much of each revenue yuan remains after operating expenses.
• 1.3% is the profit margin, indicating the share of revenue that becomes net profit.
• 10.2% is the debt-to-equity ratio, comparing total debt to shareholders' equity to gauge financial leverage.

What to watch

Hangzhou Tigermed Consulting (300347) operates in the Diagnostics & Research industry, where regulatory changes, clinical trial timelines, and drug approval cycles can affect demand for its services. As a Shenzhen-listed stock, it is part of the broader Chinese healthcare ecosystem that includes peers such as Shijiazhuang Yiling Pharmaceutical (002603), Asymchem Laboratories (Tianjin) (002821), and Shanghai RAAS Blood Products (002252). Investors often monitor revenue growth, which stands at 13% year over year, alongside margins and operating efficiency. The stock's 0.35 beta suggests lower volatility than the market, while the 35.57 – 67.85 52-week range shows the price spread over the past year.